Elicio Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Elicio Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $18.56 million for the year ending 2025.

  • Elicio Therapeutics, Inc. showed an increase of +5.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Elicio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Elicio Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 46.4%.
  • Historical annual values: Fiscal year 2025: $18.56 million | Fiscal year 2024: $17.62 million | Fiscal year 2023: $12.89 million | Fiscal year 2022: $6.16 million | Fiscal year 2021: $88.76 million | Fiscal year 2020: $34.61 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: